Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Approving cancer drugs in the UK – where is the line?

Debate has raged in recent months over decisions to approve or, in most cases, not approve several cancer treatments in the UK. While Roche's skin cancer drug Erivedge recently got the nod, Novartis's breast cancer drug Afinitor and Pfizer's lung cancer treatment Xalkori have been deemed not cost-effective for the NHS. So where is the line? At what point does a proven life-saving medication no longer become cost worthy and what should be done to reduce costs?

Go Top